膣炎治療薬市場の2030年までの予測： 疾患タイプ別、治療別、流通チャネル別、地域別の世界分析

Stratistics MRCによると、世界の膣炎治療薬市場は2023年に35億2,000万米ドルを占め、予測期間中に10.3％のCAGRで成長し、2030年までに70億1,000万米ドルに達すると予想されています。

膣炎治療薬には、膣炎として知られる膣の炎症や感染の治療を目的とした医療介入が含まれます。一般的な原因には細菌、真菌、ウイルス感染が含まれ、治療には抗菌薬、抗真菌薬、抗ウイルス薬が用いられることが多いです。さらに、ホルモンバランスの乱れや刺激物などの根本的な要因を管理することが重要です。個人個人に合わせたケアには、症状を緩和し、膣の健康を回復するために、外用薬や内服薬、生活習慣の改善、要因への対処などが含まれます。

CDCによると、米国では約30％の女性が頻繁に膣炎を経験しています。

女性の健康と膣炎に対する意識の高まり

女性の健康と膣感染症に対する意識の高まりは、膣炎治療薬の極めて重要な原動力となっています。それはヘルスケアへの積極的なアプローチを促進し、女性が早期に症状を認識し、迅速な診察を受け、予防措置を採用することを奨励します。このような意識は、教育イニシアチブを促進し、オープンな議論を促進し、膣の健康問題を取り巻く偏見を減少させる。その結果、ヘルスケアを求める行動の改善、早期診断、タイムリーな介入につながり、効果的な治療法の需要を促進します。

限られたヘルスケアアクセス

限られた医療アクセスは、膣炎治療薬における重要な阻害要因となっています。特に農村部やサービスが行き届いていない地域ではヘルスケアインフラが不十分で、医療施設や専門医の利用可能性が低下するなど、さまざまな障壁が存在します。さらに、経済的な制約やアクセスの格差により、タイムリーな診断や治療を受けられない人もいます。このような制限は、過小診断や治療の遅れを悪化させ、重要な情報や治療法の普及を妨げるため、罹患者における膣炎の効果的な管理を制限しています。

遠隔医療の普及が促進する

遠隔医療の採用増加は、遠隔診断や治療との統合により、膣炎治療薬市場に機会をもたらします。遠隔医療が拡大するにつれ、正確な放射線モニタリングツールが必要とされています。これらの機器は、画像診断や放射線治療を含む遠隔医療セッション中の放射線被ばくを遠隔評価することで、患者の安全を確保する上で極めて重要になります。遠隔医療に対応する放射線検出技術の革新は、ポータブルで使いやすく、正確な検出器を開発し、この新興国市場の需要を開拓するチャンスです。

臨床試験の課題

教育やリソースが限られているため、適切な放射線安全対策の導入や検出技術の理解が妨げられています。その結果、患者や医療従事者の放射線過剰被曝のリスクが高まり、健康に影響を及ぼす可能性があります。さらに、厳しい規制がないことやインフラ投資が不十分であることがこの問題をさらに悪化させ、放射線に関連した健康合併症の発生率が高くなる可能性があり、高度な検出ソリューションに対する需要がないため市場の成長を阻害しています。

COVID-19の影響：

COVID-19の流行は、ヘルスケアの優先順位を変えることで市場に影響を与えています。ヘルスケアシステムがパンデミック対策に注力する中、注目とリソースは膣炎のような緊急性のない症状からシフトしました。ヘルスケアへのアクセス、サプライチェーン、患者行動の混乱も、診断と治療を求めるパターンに影響を与え、パンデミック期間中の膣炎治療薬の市場ダイナミクスに影響を与えました。

予測期間中、処方薬セグメントが最大となる見込み

処方薬セグメントは、慢性疾患の有病率の増加と専門的な医療介入の必要性の増加により、予測期間中に最大になると予測されます。ヘルスケアに対する意識が高まるにつれ、特定の健康状態に対処するための処方薬に対する需要が急増しています。さらに、規制当局の承認や医薬品研究の進歩も、このセグメントの隆盛に寄与しています。

オンライン薬局セグメントは予測期間中最も高いCAGRが見込まれる

オンライン薬局分野は、ヘルスケアサービスのデジタル化、利便性、アクセシビリティの向上により、予測期間中に高い成長率を達成すると予測されます。消費者は自宅にいながら簡単に薬を購入できることを優先するため、オンライン薬局は魅力的なソリューションを提供します。遠隔医療の採用とeコマースの進歩が、このセグメントの急成長を促進しています。

最大のシェアを持つ地域

北米は、先進的なヘルスケア・インフラ、高い認知度、女性の健康に重点を置いていることが主な要因であり、市場を独占する立場にあります。この地域のトップシェアは、確立された研究開発活動、強力な規制枠組み、革新的な治療法の採用に対する積極的なアプローチによってさらに後押しされています。膣炎の罹患率の増加は、高齢化人口の増加と相まって、効果的な治療薬の需要に寄与しており、膣炎治療薬市場で最大の市場シェアを獲得する上で北米の極めて重要な役割を強化しています。

CAGRが最も高い地域：

アジア太平洋地域は、認知度の向上、ヘルスケアインフラの増加、女性の健康重視の高まりにより、市場が大きく成長しています。ヘルスケアサービスへのアクセスの改善、ライフスタイルの変化、膣炎の罹患率の上昇などの要因が、この地域の拡大姿勢に寄与しています。さらに、医学研究と技術の進歩は、政府の支援的なイニシアチブと相まって、革新的な膣炎治療薬の市場開拓と採用に有利な環境を作り出し、アジア太平洋地域の大幅な市場成長を促進しています。

無料のカスタマイズ提供：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の膣炎治療薬市場：疾患タイプ別

• 萎縮性膣炎
• 細菌性膣炎（BV）
• トリコモナス症
• 外陰膣カンジダ症（VVC）
• その他の疾患タイプ

第6章 世界の膣炎治療薬市場：治療別

• 処方薬
• 自然療法とハーブ療法
• 市販薬（OTC）
• プロバイオティクスと膣座薬

第7章 世界の膣炎治療薬市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル

第8章 世界の膣炎治療薬市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Astellas Pharma
• AstraZeneca PLC
• Bausch Health Companies Inc
• Bayer AG
• Biocon Limited
• Cipla Inc.
• Ferring Pharmaceuticals
• GlaxoSmithKline plc
• Hologic, Inc.
• Johnson & Johnson
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Perrigo Company plc
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• TherapeuticsMD, Inc.

List of Tables

• Table 1 Global Vaginitis Therapeutics Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
• Table 3 Global Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
• Table 4 Global Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
• Table 5 Global Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
• Table 6 Global Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
• Table 7 Global Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
• Table 8 Global Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
• Table 9 Global Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
• Table 10 Global Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
• Table 11 Global Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
• Table 12 Global Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
• Table 13 Global Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 14 Global Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 15 Global Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 16 Global Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 17 Global Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 18 North America Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 19 North America Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
• Table 20 North America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
• Table 21 North America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
• Table 22 North America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
• Table 23 North America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
• Table 24 North America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
• Table 25 North America Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
• Table 26 North America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
• Table 27 North America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
• Table 28 North America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
• Table 29 North America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
• Table 30 North America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 31 North America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 32 North America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 33 North America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 34 North America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 35 Europe Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 36 Europe Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
• Table 37 Europe Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
• Table 38 Europe Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
• Table 39 Europe Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
• Table 40 Europe Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
• Table 41 Europe Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
• Table 42 Europe Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
• Table 43 Europe Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
• Table 44 Europe Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
• Table 45 Europe Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
• Table 46 Europe Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
• Table 47 Europe Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 48 Europe Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 49 Europe Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 50 Europe Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 51 Europe Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 52 Asia Pacific Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 53 Asia Pacific Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
• Table 54 Asia Pacific Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
• Table 55 Asia Pacific Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
• Table 56 Asia Pacific Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
• Table 57 Asia Pacific Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
• Table 58 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
• Table 59 Asia Pacific Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
• Table 60 Asia Pacific Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
• Table 61 Asia Pacific Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
• Table 62 Asia Pacific Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
• Table 63 Asia Pacific Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
• Table 64 Asia Pacific Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 65 Asia Pacific Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 66 Asia Pacific Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 67 Asia Pacific Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 68 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 69 South America Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 70 South America Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
• Table 71 South America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
• Table 72 South America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
• Table 73 South America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
• Table 74 South America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
• Table 75 South America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
• Table 76 South America Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
• Table 77 South America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
• Table 78 South America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
• Table 79 South America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
• Table 80 South America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
• Table 81 South America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 82 South America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 83 South America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 84 South America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 85 South America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 86 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 87 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
• Table 88 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
• Table 89 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
• Table 90 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
• Table 91 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
• Table 92 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
• Table 93 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
• Table 94 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
• Table 95 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
• Table 96 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
• Table 97 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
• Table 98 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 99 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 100 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 101 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 102 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

According to Stratistics MRC, the Global Vaginitis Therapeutics Market is accounted for $3.52 billion in 2023 and is expected to reach $7.01 billion by 2030 growing at a CAGR of 10.3% during the forecast period. Vaginitis therapeutics encompasses medical interventions aimed at treating inflammation or infection of the vagina, a condition known as vaginitis. Common causes include bacterial, fungal or viral infections and treatment often involves antimicrobial medications, antifungals, or antivirals. Additionally, managing underlying factors like hormonal imbalances or irritants is crucial. Personalized care may include topical or oral medications, lifestyle modifications and addressing contributing factors to alleviate symptoms and restore vaginal health.

According to the CDC, about 30% of women in the U.S. experience vaginitis at frequent intervals.

Market Dynamics:

Driver:

Heightened awareness about women's health and vaginal infections

Increased awareness about women's health and vaginal infections acts as a pivotal driver in vaginitis therapeutics. It fosters a proactive approach to healthcare, encouraging women to recognize symptoms early, seek prompt medical attention and adopt preventive measures. This awareness promotes education initiatives, facilitates open discussions and reduces stigma surrounding vaginal health issues. Consequently, it leads to improved healthcare-seeking behaviour, earlier diagnosis, and timely intervention, driving the demand for effective therapies.

Restraint:

Limited healthcare access

Limited healthcare access serves as a significant restraint in vaginitis therapeutics. It encompasses various barriers such as inadequate healthcare infrastructure, especially in rural or underserved areas, leading to reduced availability of medical facilities and specialists. Additionally, financial constraints and disparities in access prevent some individuals from seeking timely diagnosis and treatment. This limitation exacerbates underdiagnosis, delays in care and impedes the dissemination of crucial information and treatments, thereby restricting effective management of vaginitis among affected populations.

Opportunity:

Increasing adoption of telemedicine facilitates

The growing adoption of telehealth presents an opportunity in the vaginitis therapeutics market due to its integration with remote diagnostics and treatments. As telehealth expands, there is a need for accurate radiation monitoring tools. These devices become crucial in ensuring patient safety by remotely assessing radiation exposure during telemedicine sessions involving imaging or radiation therapies. Innovations in radiation detection technologies catering to telehealth settings offer a chance for companies to develop portable, user-friendly, and precise detectors, thereby tapping into this evolving market demand.

Threat:

Clinical trial challenges

Limited education and resources hinder the adoption of proper radiation safety measures and the understanding of detection technologies. This can lead to increased risks of overexposure to radiation for both patients and healthcare workers, impacting their health. Additionally, the absence of stringent regulations and insufficient infrastructure investment further exacerbate this issue, potentially resulting in higher incidences of radiation-related health complications and impeding the market's growth due to a lack of demand for advanced detection solutions.

Covid-19 Impact:

The COVID-19 pandemic has influenced the market by altering healthcare priorities. With healthcare systems focusing on combating the pandemic, attention and resources shifted away from non-emergency conditions like vaginitis. Disruptions in healthcare access, supply chains, and patient behaviour also affected diagnosis and treatment-seeking patterns, impacting the market dynamics for vaginitis therapeutics during the pandemic period.

The prescription drugs segment is expected to be the largest during the forecast period

The prescription drugs segment is anticipated to be the largest during the forecast period owing to the growing prevalence of chronic diseases and the increasing need for specialized medical interventions. As healthcare awareness rises, there is a surge in demand for prescription medications to address specific health conditions. Additionally, regulatory approvals and advancements in pharmaceutical research contribute to the prominence of this segment.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

The online pharmacies segment is projected to achieve a high growth rate during the forecast period due to increasing digitalization, convenience and accessibility of healthcare services. As consumers prioritise the ease of purchasing medications from the comfort of their homes, online pharmacies offer a compelling solution. The adoption of telemedicine, coupled with advancements in e-commerce, fosters the rapid growth of this segment.

Region with largest share:

North America is positioned to dominate the market, primarily attributed to advanced healthcare infrastructure, high awareness levels, and a robust emphasis on women's health. The region's leading market share is further propelled by well-established research and development activities, a strong regulatory framework, and a proactive approach toward adopting innovative therapies. Increasing incidences of vaginitis, coupled with a growing aging population, contribute to the demand for effective therapeutics, reinforcing North America's pivotal role in capturing the largest market share in the vaginitis therapeutics market.

Region with highest CAGR:

The Asia-Pacific region is experiencing significant growth in the market due to rising awareness, increasing healthcare infrastructure and a growing emphasis on women's health. Factors such as improved access to healthcare services, changing lifestyles, and a rising incidence of vaginitis contribute to the region's poised expansion. Additionally, advancements in medical research and technology, coupled with supportive government initiatives, create a favourable environment for the development and adoption of innovative vaginitis therapeutics, driving substantial market growth in the Asia-Pacific region.

Key players in the market

Some of the key players in Vaginitis Therapeutics Market include Astellas Pharma, AstraZeneca PLC, Bausch Health Companies Inc, Bayer AG, Biocon Limited, Cipla Inc., Ferring Pharmaceuticals, GlaxoSmithKline plc, Hologic, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Perrigo Company plc, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc.

Key Developments:

In January 2023, Astellas Pharma acquired Shionogi & Co.'s global women's health franchise, which includes the Vagifem vaginal ring for the treatment of recurrent vulvovaginal candidiasis (RVVC).

In May 2022, Bayer acquired FemTec, including Vagisan, a vaginal moisturizer. Additionally, Seres Therapeutics introduced SER-109, a microbiome-based therapy for recurrent vulvovaginal candidiasis (RVVC).

In April 2022, Pfizer introduced Daivobet, a topical cream combining steroids and vitamin D, designed to treat vulvovaginal candidiasis (VVC). Daivobet stands as the sole FDA-approved topical cream with this combination for VVC treatment.

Disease Types Covered:

• Atrophic Vaginitis
• Bacterial vaginosis (BV)
• Trichomoniasis
• Vulvovaginal Candidiasis (VVC)
• Other Disease Types

Treatments Covered:

• Prescription Drugs
• Natural and Herbal Remedies
• Over-the-counter (OTC) Drugs
• Probiotics and Vaginal Suppositories

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Vaginitis Therapeutics Market, By Disease Type

• 5.1 Introduction
• 5.2 Atrophic Vaginitis
• 5.3 Bacterial vaginosis (BV)
• 5.4 Trichomoniasis
• 5.5 Vulvovaginal Candidiasis (VVC)
• 5.6 Other Disease Types

6 Global Vaginitis Therapeutics Market, By Treatment

• 6.1 Introduction
• 6.2 Prescription Drugs
• 6.3 Natural and Herbal Remedies
• 6.4 Over-the-counter (OTC) Drugs
• 6.5 Probiotics and Vaginal Suppositories

7 Global Vaginitis Therapeutics Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies
• 7.5 Other Distribution Channels

8 Global Vaginitis Therapeutics Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Astellas Pharma
• 10.2 AstraZeneca PLC
• 10.3 Bausch Health Companies Inc
• 10.4 Bayer AG
• 10.5 Biocon Limited
• 10.6 Cipla Inc.
• 10.7 Ferring Pharmaceuticals
• 10.8 GlaxoSmithKline plc
• 10.9 Hologic, Inc.
• 10.10 Johnson & Johnson
• 10.11 Lupin Pharmaceuticals, Inc.
• 10.12 Merck & Co., Inc.
• 10.13 Mylan N.V.
• 10.14 Novartis AG
• 10.15 Perrigo Company plc
• 10.16 Pfizer Inc.
• 10.17 Sanofi
• 10.18 Sun Pharmaceutical Industries Ltd.
• 10.19 Teva Pharmaceutical Industries Ltd.
• 10.20 TherapeuticsMD, Inc.